Document is current
Any future updates will be listed below
-
Authors
Shah, Binita https://orcid.org/0000-0002-6084-3355
Hunkeler, Moritz https://orcid.org/0000-0003-0246-1188
Bratt, Ariana
Yue, Hong https://orcid.org/0000-0003-4347-3193
Jaen Maisonet, Isabella https://orcid.org/0000-0003-4996-3492
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Buhrlage, Sara J. https://orcid.org/0000-0003-4562-1823
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA262188, 5F31CA281197-02, R01CA233800)
- License Information
-
More Information
Article History
Received: 7 November 2024
Accepted: 12 August 2025
First Online: 28 August 2025
Competing interests
: E.S.F. is a founder, scientific advisory board (SAB) member, and equity holder of Civetta Therapeutics, Proximity Therapeutics, Stelexis Biosciences, Anvia Therapeutics (also board of directors) and Neomorph, Inc. (also board of directors). He is an equity holder and SAB member for Avilar Therapeutics, Photys Therapeutics, and Ajax Therapeutics and an equity holder in Lighthorse Therapeutics and CPD4, Inc. (also board of directors). E.S.F. is a consultant to Novartis, EcoR1 Capital, Odyssey and Deerfield. The Fischer lab receives or has received research funding from Deerfield, Novartis, Ajax, Interline, Bayer and Astellas. S.J.B. is a founder, SAB member, and equity holder of Entact Bio and receives or has received sponsored research funding from Novartis Institutes for Biomedical Research, AbbVie, Kinogen, TUO Therapeutics, Takeda, and Pivotal Life Sciences. The remaining authors declare no competing interests.
